Nasdaq
华尔街日报One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts
Deep and durable ongoing responses with median time on treatment of 15 months
Read more at globenewswire.comPliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Barchart·12/04/2025 06:30:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.